LEXINGTON, Mass., March 12, 2026 — Curis, Inc. (NASDAQ: CRIS), a biotech firm concentrating on the development of emavusertib (CA-4948), an orally administrable, small – molecule IRAK4 and FLT3 inhibitor, announced today that the Company will disclose its fourth – quarter 2025 financial and operational results on Thursday, March 19, 2026, at 4:00 p.m. ET. The management will hold a conference call and a simultaneous webcast on the same day at 4:30 p.m. ET.
Participants can join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations. Alternatively, a live audio webcast can be accessed here or from the investor section of the Curis website. A replay of the conference call will be available at www.curis.com.
About Curis, Inc.
Curis is a biotech company centered on the development of emavusertib, an orally available, small – molecule IRAK4 and FLT3 inhibitor. Emavusertib is currently under evaluation in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) of emavusertib in combination with the BTK inhibitor, ibrutinib, for patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) and in the TakeAim CLL Phase 2 study (CA-4948-203) of emavusertib in combination with the BTK inhibitor, zanubrutinib, for chronic lymphocytic leukemia (CLL). The Company has finished its monotherapy and combination studies in acute myeloid leukemia (AML). With additional funding, we plan to continue the development of emavusertib as a monotherapy and in combination with other agents in AML. Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of PCNSL, AML and MDS and from the European Commission for the treatment of PCNSL. Curis, through its 2015 collaboration with Aurigene Discovery Technologies Limited, holds the exclusive license to emavusertib (CA-4948). For more information, visit Curis’s website at www.curis.com.
SOURCE Curis, Inc.